Press Releases Year: - Any -201920182017201620152014 Items per page 102550 Date Title and Summary Additional Formats Toggle SummaryMay 24, 2019 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummaryMay 14, 2019 Alder BioPharmaceuticals® to Present at Two Upcoming May Investor Conferences View HTML Toggle SummaryMay 08, 2019 Alder BioPharmaceuticals® Presents New Analysis of Patient-Reported Outcomes Following Eptinezumab Treatment for Migraine Prevention View HTML Toggle SummaryMay 06, 2019 Alder BioPharmaceuticals® Presents New Data Demonstrating Consistent, Early and Robust Prevention with Eptinezumab for Episodic and Chronic Migraine across Four Clinical Trials View HTML Toggle SummaryMay 02, 2019 Alder BioPharmaceuticals® Reports First Quarter 2019 Financial and Operating Results View HTML Toggle SummaryApr 26, 2019 Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results View HTML Toggle SummaryApr 26, 2019 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Toggle SummaryApr 23, 2019 Alder BioPharmaceuticals® to Present New Analyses of Eptinezumab’s Clinical Trial Data Describing Early, Robust Migraine Prevention and Quality of Life Impact at 2019 American Academy of Neurology Annual Meeting View HTML Toggle SummaryApr 22, 2019 U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab View HTML Toggle SummaryApr 12, 2019 Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) View HTML Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
